Western blot analysis of extracts from HeLa cells, untreated (-) or treated with ABT-263 (Navitoclax) (10 μM, 24 hr; +), using Cleaved Caspase-9 (Asp315) (D8I9E) Rabbit mAb #20750 (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower).
Chemical structure of ABT-263 (Navitoclax).
ABT-263 (Navitoclax) is supplied as a lyophilized powder. For a 5 mM stock, reconstitute 5 mg of powder in 1.0 ml of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
|Molecular Weight||974.6 g/mol|
|Solubility||Soluble in DMSO at 25 mg/ml.|
ABT-263 (Navitoclax) is a potent and orally bioavailable Bcl-2 family inhibitor. This small molecule mimetic of BH3 domains specifically binds to Bcl-2, Bcl-xL, and Bcl-W with a Ki value of less than 1 nM (1). ABT-263 (Navitoclax) has been shown to have antitumor effects on small cell lung cancer (SCLC) xenograft models, resulting in complete tumor regression in some cases (2). Studies have shown that ABT-263 (Navitoclax) can enhance the effectiveness of chemotherapeutic and targeted agents against solid tumors (3). ABT-263 (Navitoclax) induces apoptosis, particularly in certain types of senescent cells (4,5).